Head-to-head evidence
Beclomethasone (QVAR) vs Ciclesonide (XRP1526)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Asthma
Shared mechanism: Glucocorticoid receptor · full Asthma pipeline
Beclomethasone (QVAR)
Marketed by Teva Pharmaceutical Industries
NCT00109668 · Phase 3 · completed
This was a randomized, double-blind, placebo-controlled trial with over 400 patients, which gives it solid design fundamentals. However, no results have been posted, and the record does not state what the primary outcome measure actually was, so the strength of the eventual evidence cannot yet be confirmed.
Ciclesonide (XRP1526)
Developed by Sanofi
NCT00174720 · Phase 3 · completed
In this randomized, double-blind, placebo-controlled Phase 3 trial, 708 patients with asthma were randomized to one of several ciclesonide dosing regimens or placebo. Ciclesonide produced significantly greater improvements in lung function (FEV1) than placebo, both averaged over weeks 12-16 and at week 16 alone.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Beclomethasone (QVAR)'s landscape · Ciclesonide (XRP1526)'s landscape